Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-12.60 Insider Own1.40% Shs Outstand67.49M Perf Week9.16%
Market Cap1.38B Forward P/E- EPS next Y-9.21 Insider Trans-0.11% Shs Float66.56M Perf Month15.79%
Income-842.10M PEG- EPS next Q-2.65 Inst Own81.30% Short Float8.67% Perf Quarter-23.04%
Sales50.20M P/S27.43 EPS this Y30.50% Inst Trans0.03% Short Ratio5.02 Perf Half Y-27.12%
Book/sh14.59 P/B1.41 EPS next Y23.90% ROA-49.40% Target Price24.53 Perf Year-63.06%
Cash/sh12.57 P/C1.64 EPS next 5Y- ROE-66.50% 52W Range17.14 - 59.32 Perf YTD-52.37%
Dividend- P/FCF- EPS past 5Y-15.60% ROI-46.00% 52W High-64.77% Beta1.50
Dividend %- Quick Ratio3.60 Sales past 5Y77.90% Gross Margin59.40% 52W Low21.94% ATR0.79
Employees1213 Current Ratio3.60 Sales Q/Q-96.20% Oper. Margin- RSI (14)64.89 Volatility4.12% 4.11%
OptionableYes Debt/Eq0.00 EPS Q/Q-907.50% Profit Margin- Rel Volume2.22 Prev Close20.61
ShortableYes LT Debt/Eq0.00 EarningsAug 09 BMO Payout- Avg Volume1.15M Price20.90
Recom2.80 SMA2010.07% SMA5011.31% SMA200-29.62% Volume2,550,141 Change1.41%
Aug-10-21Resumed William Blair Mkt Perform
Aug-10-21Downgrade Wells Fargo Overweight → Equal Weight $60 → $25
Aug-10-21Downgrade Goldman Buy → Neutral $63 → $23
Aug-10-21Downgrade Canaccord Genuity Buy → Hold
Aug-09-21Downgrade SVB Leerink Outperform → Mkt Perform
Jul-01-21Downgrade Berenberg Buy → Hold $35
Mar-10-21Upgrade Mizuho Neutral → Buy $34 → $69
Feb-17-21Downgrade JP Morgan Overweight → Neutral $76 → $39
Feb-16-21Downgrade William Blair Outperform → Mkt Perform
Feb-16-21Downgrade Wedbush Outperform → Neutral
Feb-16-21Downgrade BofA Securities Buy → Neutral
Dec-09-20Downgrade Maxim Group Buy → Hold
Nov-11-20Initiated Berenberg Buy
Nov-05-20Downgrade Stifel Buy → Hold $77 → $51
Nov-05-20Downgrade BMO Capital Markets Outperform → Market Perform $108 → $56
Nov-05-20Downgrade Barclays Overweight → Equal Weight
Nov-02-20Upgrade William Blair Mkt Perform → Outperform
Oct-20-20Initiated Mizuho Buy $123
May-13-20Initiated RBC Capital Mkts Outperform $100
Mar-27-20Upgrade Stifel Hold → Buy $70
Oct-08-21 04:54PM  
Sep-22-21 07:03AM  
Sep-21-21 04:15PM  
Sep-13-21 08:00AM  
Sep-08-21 11:30AM  
07:30AM  
Sep-07-21 04:05PM  
Aug-13-21 10:50PM  
Aug-11-21 01:22AM  
Aug-09-21 04:04PM  
12:38PM  
08:47AM  
08:15AM  
07:00AM  
06:38AM  
Aug-05-21 04:05PM  
Jul-28-21 03:03PM  
08:00AM  
Jul-23-21 10:50PM  
Jul-21-21 05:00AM  
01:59AM  
Jul-13-21 01:16PM  
Jul-10-21 09:01AM  
Jul-09-21 10:48AM  
07:30AM  
Jul-04-21 07:49AM  
Jun-15-21 09:32AM  
Jun-11-21 10:50PM  
05:00AM  
Jun-07-21 05:25PM  
04:12PM  
04:05PM  
09:53AM  
08:50AM  
08:00AM  
Jun-04-21 11:31AM  
Jun-02-21 04:05PM  
May-25-21 06:55AM  
May-21-21 08:00AM  
May-19-21 05:00PM  
May-05-21 06:35PM  
04:05PM  
May-03-21 05:59PM  
03:01PM  
08:00AM  
May-01-21 11:15AM  
06:10AM  
Apr-22-21 05:54PM  
Apr-21-21 09:35AM  
01:24AM  
Apr-20-21 07:30AM  
Apr-14-21 06:30AM  
Apr-13-21 04:22PM  
03:20PM  
02:47PM  
10:50AM  
10:03AM  
09:42AM  
09:40AM  
09:00AM  
06:30AM  
01:00AM  
Apr-12-21 05:27PM  
04:00PM  
03:48PM  
03:22PM  
01:25PM  
12:50PM  
12:00PM  
11:20AM  
09:57AM  
09:00AM  
08:00AM  
06:10AM  
12:05AM  
Apr-11-21 01:00PM  
06:22AM  
Apr-09-21 09:00PM  
06:28PM  
05:00PM  
03:13PM  
01:45PM  
11:45AM  
10:58AM  
10:45AM  
10:30AM  
10:00AM  
Apr-08-21 02:20PM  
01:27PM  
12:59PM  
12:55PM  
11:30AM  
10:30AM  
09:56AM  
09:35AM  
Apr-07-21 01:40PM  
01:00PM  
12:45PM  
12:40PM  
10:00AM  
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases and cancer. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent -thalassemia; LentiGlobin for the treatment of sickle cell disease; and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company's product candidates in oncology include Idecabtagene vicleucel and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has collaboration and license agreements with Bristol-Myers Squibb, Regeneron Pharmaceuticals, Inc., Novartis Pharma AG, Orchard Therapeutics Limited, Medigene AG, Novo Nordisk A/S, Forty Seven, Inc., Gritstone Oncology, Inc., Magenta Therapeutics, Inc., the Seattle Children's Research Institute, University of North Carolina, and the Fred Hutchinson Cancer Research Center. bluebird bio, Inc. has a strategic alliance with National Resilience, Inc. to research, development, and delivery of cell therapies. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Obenshain AndrewPresident of SGDJun 04Sale30.7551115,71539,597Jun 08 04:26 PM
Gregory Philip DChief Scientific OfficerMay 03Sale30.15391,17646,829May 05 04:45 PM
Obenshain AndrewPresident of SGDMay 03Sale30.152987440,108May 05 04:46 PM
Leschly NickPresident and CEOMay 03Sale30.1544413,387306,692May 05 04:44 PM
Cole JasonChief Operating andMay 03Sale30.15381,14647,922May 05 04:43 PM
Obenshain AndrewPresident of SGDApr 05Sale30.212987640,137Apr 07 04:43 PM
Davidson DavidChief Medical OfficerApr 05Sale30.21421,26947,787Apr 07 04:42 PM
Cole JasonChief Operating andApr 05Sale30.21371,11847,960Apr 07 04:42 PM
Gregory Philip DChief Scientific OfficerApr 05Sale30.21391,17846,868Apr 07 04:43 PM
Leschly NickPresident and CEOApr 05Sale30.2144413,411307,136Apr 07 04:43 PM
Leschly NickPresident and CEOMar 04Option Exercise5.50203,3551,118,534307,580Mar 08 04:50 PM
Gregory Philip DChief Scientific OfficerMar 02Sale29.58391,15446,907Mar 04 04:46 PM
Cole JasonChief Operating andMar 02Sale29.58381,12447,997Mar 04 04:46 PM
Davidson DavidChief Medical OfficerMar 02Sale29.58421,24247,829Mar 04 04:46 PM
Obenshain AndrewPresident of SGDMar 02Sale29.58341,00640,166Mar 04 04:46 PM
Leschly NickPresident and CEOMar 02Sale29.5844413,134104,225Mar 04 04:46 PM
Davidson DavidChief Medical OfficerFeb 17Sale28.1669819,65747,871Feb 18 05:22 PM
Obenshain AndrewPresident of SGDFeb 17Sale28.1674921,09340,200Feb 18 05:22 PM
Gregory Philip DChief Scientific OfficerFeb 17Sale28.1666418,69946,946Feb 18 05:22 PM
Burnett KatyPrincipal Accounting OfficerFeb 17Sale28.1651814,5884,097Feb 18 05:22 PM
Baird William D IIIChief Financial OfficerFeb 17Sale28.1669319,51635,529Feb 18 05:22 PM
Cole JasonChief Operating andFeb 17Sale28.1666518,72748,035Feb 18 05:22 PM
Baird William D IIIChief Financial OfficerFeb 12Sale45.521,21655,35221,581Feb 17 05:23 PM
Obenshain AndrewPresident of SGDFeb 02Sale45.93341,56123,884Feb 04 04:04 PM
Gregory Philip DChief Scientific OfficerFeb 02Sale45.93592,71032,948Feb 04 04:03 PM
Cole JasonChief Operating andFeb 02Sale45.93381,74532,785Feb 04 04:03 PM
Leschly NickPresident and CEOFeb 02Sale45.9359427,28086,669Feb 04 04:04 PM
Davidson DavidChief Medical OfficerFeb 02Sale45.93632,89336,298Feb 04 04:04 PM
FINGER ALISON CECILYChief Commercial OfficerJan 06Sale45.051,81481,72725,103Jan 08 05:57 PM
Leschly NickPresident and CEOJan 06Sale45.0510,095454,81487,263Jan 08 06:18 PM
Baird William D IIIChief Financial OfficerJan 06Sale45.0594942,75622,797Jan 08 05:57 PM
Gregory Philip DChief Scientific OfficerJan 06Sale45.052,754124,07733,007Jan 08 05:56 PM
Davidson DavidChief Medical OfficerJan 06Sale45.053,167142,68436,361Jan 08 05:57 PM
Cole JasonChief Operating andJan 06Sale45.052,358106,23632,823Jan 08 05:56 PM
Smith-Farrell JoanneCOO, OncologyJan 06Sale45.051,28757,98420,609Jan 08 05:56 PM
Smith-Farrell JoanneCOO, OncologyJan 05Sale44.95421,88821,896Jan 08 05:56 PM
Cole JasonChief Operating andJan 05Sale44.95431,93335,181Jan 08 05:56 PM
Davidson DavidChief Medical OfficerJan 05Sale44.95482,15839,528Jan 08 05:57 PM
Gregory Philip DChief Scientific OfficerJan 05Sale44.95452,02335,761Jan 08 05:56 PM
Leschly NickPresident and CEOJan 05Sale44.9533314,96997,358Jan 08 06:18 PM
FINGER ALISON CECILYChief Commercial OfficerJan 05Sale44.95401,79826,917Jan 08 05:57 PM
Burnett KatyPrincipal Accounting OfficerDec 03Sale46.091235,6691,460Dec 04 04:49 PM
Leschly NickPresident and CEODec 02Sale46.2044420,51297,691Dec 04 04:48 PM
Davidson DavidChief Medical OfficerDec 02Sale46.20642,95739,576Dec 04 04:48 PM
Gregory Philip DChief Scientific OfficerDec 02Sale46.20592,72635,806Dec 04 04:48 PM
Cole JasonChief Operating andDec 02Sale46.20381,75635,224Dec 04 04:48 PM
Smith-Farrell JoanneCOO, OncologyDec 02Sale46.20381,75621,938Dec 04 04:48 PM
FINGER ALISON CECILYChief Commercial OfficerDec 02Sale46.20361,66326,957Dec 04 04:48 PM
Leschly NickPresident and CEONov 02Sale52.9444423,50698,135Nov 04 04:04 PM
Davidson DavidChief Medical OfficerNov 02Sale52.94633,33539,640Nov 04 04:05 PM
Gregory Philip DChief Scientific OfficerNov 02Sale52.93593,12335,865Nov 04 04:05 PM
Cole JasonChief Operating andNov 02Sale52.97371,96035,262Nov 04 04:05 PM
Smith-Farrell JoanneCOO, OncologyNov 02Sale52.97371,96021,976Nov 04 04:05 PM
FINGER ALISON CECILYChief Commercial OfficerNov 02Sale52.99351,85526,993Nov 04 04:05 PM